Search results
Results from the WOW.Com Content Network
Delayed Gadolinium-enhanced MR Imaging of Articular Cartilage: Three-dimensional T1 Mapping with Variable Flip Angles and B1 Correction; Toward Imaging Biomarkers for Glycosaminoglycans; Longitudinal Evaluation of Cartilage Composition of Matrix-Associated Autologous Chondrocyte Transplants with 3-T Delayed Gadolinium-Enhanced MRI of Cartilage
Continuing evidence of the retention of gadolinium in brain and other tissues following exposure to gadolinium containing contrast media, led to a safety review by the Committee for Medicinal Products for Human Use (CHMP) which led the EMA to restrict or suspend authorization for the intravenous use of most brands of linear gadolinium-based ...
Late gadolinium enhancement (LGE) and T1 mapping allow infarction and fibrosis to be identified for characterizing cardiomyopathy and assessing viability. [8] Magnetic resonance angiography may be performed with or without contrast medium and is used to assess congenital or acquired abnormalities of the coronary arteries and great vessels. [9]
A 2015 study found gadolinium deposited in the brain tissue of people who had received gadodiamide. [8] Other studies using post-mortem mass spectrometry found most of the deposit remained at least 2 years after an injection and deposit also in individuals with no kidney issues.
The contrast agents used for DCE-MRI are often gadolinium based. Interaction with the gadolinium (Gd) contrast agent (commonly a gadolinium ion chelate) causes the relaxation time of water protons to decrease, and therefore images acquired after gadolinium injection display higher signal in T1-weighted images indicating the present of the agent.
It consists of the organic acid DOTA as a chelating agent, and gadolinium (Gd 3+), and is used in form of the meglumine salt (gadoterate meglumine). [ 4 ] [ 5 ] The paramagnetic property of gadoteric acid reduces the T1 relaxation time (and to some extent the T2 and T2* relaxation times) in MRI , which is the source of its clinical utility.
Gadoversetamide is a gadolinium-based MRI contrast agent, particularly for imaging of the brain, spine and liver. [1] [2] It is marketed under the trade name OptiMARK.
Nanoparticles of gadolinium oxide is a potential contrast agent for magnetic resonance imaging (MRI). A dextran-coated preparation of 20–40 nm sized gadolinium oxide particles had a relaxivity of 4.8 s −1 mM −1 per gadolinium ion at 7.05 T (an unusually high field compared to the clinically used MRI scanners which mostly range from 0.5 to ...